These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 19644384)

  • 1. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
    Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
    White KL; Kulkarni R; McColl DJ; Rhee MS; Szwarcberg J; Cheng AK; Miller MD
    Antivir Ther; 2015; 20(3):317-27. PubMed ID: 25321623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
    McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
    HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.